After S. agalactiae infection, the pEGFP-Gal8-L injected group had a better survival rate than the other groups, which suggests that OnGal8-L may be promising for applying as a molecular adjuvant in the development of vaccine against bacterial infection. The gene discussed is LGALS8; the disease is bacterial infectious disease.